CARDIOVASCULAR JOURNAL OF AFRICA • Vol 21, No 1, January/February 2010
6
AFRICA
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving
16.
HH,
et al
. Effects of losartan on renal and cardiovascular outcomes in
patients with type 2 diabetes and nephropathy.
N Engl J Med
2001;
345
:
861–869.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB,
17.
et al
.
Renoprotective effect of the angiotensin-receptor antagonist irbesartan
in patients with nephropathy due to type 2 diabetes.
N Engl J Med
2001;
345
: 851–859.
Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen
18.
S, Arner P. The effect of irbesartan on the development of diabetic
nephropathy in patients with type 2 diabetes.
N Engl J Med
2001;
345
:
870–878.
Caramori ML, Kim Y, Huang C, Fish AJ, Rich SS, Miller ME, Russell
19.
G, Mauer M. Cellular basis of diabetic nephropathy. 1. Study design and
renal structural–functional relationships in patients with long-standing
type 1 diabetes.
Diabetes
2002;
51
: 506–513.
Jafar TH, Schmid CH, Landa M,
20.
et al
, for the ACE Inhibition in
Progressive Renal Disease study group. Angiotensin-converting enzyme
inhibitors and progression of nondiabetic renal disease.
Ann Intern Med
2001:
135
: 73–87.
Kunz R, Friedrich C, Wolbers M, Mann JFE. Meta-analysis: Effect
21.
of monotherapy and combination therapy with inhibitors of the renin-
angiotensin system on proteinuria in renal disease.
Ann Intern Med
2008;
148
: 30–48.
Kunz R, Wolbers M, Glass T, Mann JFE. The COOPERATE trial: a letter
22.
of concern.
Lancet
2008;
371
: 1575.
Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T.
23.
Combination treatment of angiotensin-II receptor blocker and angio-
tensin-converting-enzyme inhibitor in non-diabetic renal disease
(COOPERATE): a randomised controlled trial.
Lancet
2003;
361
:117–
124.
O’Seaghdha CM, Perkovic V, Lam TH,
24.
et al
; on behalf of the Asia
Pacific Cohort Studies Collaboration. Blood pressure is a major risk
factor for renal death. An analysis of 560 352 participants from the Asia-
Pacific region.
Hypertension
2009;
54
: 509–515.
Hsu CY. Does treatment of non-malignant hypertension reduce the inci-
25.
dence of renal dysfunction? A meta-analysis of 10 randomised, control-
led trials.
J Hum Hypertens
2001:
15
: 99–106.
The ALLHAT officers and coordinators for the ALLHAT Collaborative
26.
Research Group. Major outcomes in high-risk hypertensive patients
randomized to angiotensin-converting enzyme inhibitor or calcium
channel blocker vs diuretic.
J Am Med Assoc
2002;
288
: 2981–2997.
Agodoa L, Appel L, Bakris GL,
27.
et al
; for the African American Study
of Kidney Disease and Hypertension (AASK) Study Group.
J Am Med
Assoc
2001;
285
: 2719–2728.
Hoy WE, Wang Z, Baker PRA, Kelly AM. Reduction in natural death
28.
and renal failure from systematic screening and treatment program in an
Australian aboriginal community.
Kid Int
2003;
63
: S66–S73.
Heart Outcomes Prevention Evaluation (HOPE) study investigators.
29.
Effects of ramipril on cardiovascular and microvascular outcomes in
people with diabetes mellitus: results of the HOPE and MICRO-HOPE
substudy.
Lancet
2000;
355
: 253–259.
Mann JFE, Schmieder RE, McQueen M,
30.
et al
, on behalf of the
ONTARGET investigators. Renal outcomes with telmisartan, ramipril,
or both, in people at high vascular risk (the ONTARGET study): a
multicentre, randomised, double-blind, controlled trial.
Lancet
2008;
372
: 547–553.
Balamuthusamy S, Srinivasan L, Verma M,
31.
et al
. Renin angiotensin
system blockade and cardiovascular outcomes in patients with chronic
kidney disease and proteinuria: a meta-analysis.
Am Heart J
2009;
155
:
791–805.
Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-asso-
32.
ciated elevations in serum creatinine. Is this a cause for concern?
Arch
Intern Med
2000;
160
: 685–693.
